Robert Douglas Brooks

Dr. Robert Douglas Brooks

Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2007 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
PTPatrick S Tarpey
Patrick S Tarpey
FRF Lucy Raymond
F Lucy Raymond
LNLam S Nguyen
Lam S Nguyen
JRJayson Rodriguez
Jayson Rodriguez
AHAnna Hackett
Anna Hackett
JGJozef Gecz
Jozef Gecz

1 April 2010 in Physiology
Verified
Journal Article
Closed access
EPEmma J. Parkinson-Lawrence
Emma J. Parkinson-Lawrence
TSTetyana Shandala
Tetyana Shandala
MPMark Prodoehl
Mark Prodoehl
RPRevecca Plew
Revecca Plew
GBGlenn N. Borlace
Glenn N. Borlace
Doug BrooksDoug Brooks
Doug Brooks
The discovery over five decades ago of the lysosome, as a degradative organelle and its dysfunction in lysosomal storage disorder patients, was both insightful and simple in concept. Here, we review some of the history and pathophysiology of lysosomal storage disorders to show how they have impacted on our knowledge of lysosomal biology. Although a significant amount of information has been accrued on the molecular genetics and biochemistry of lysosomal storage disorders, we still do not fully understand the mechanistic link between the storage material and disease pathogenesis. However, the accumulation of undegraded substrate(s) can disrupt other lysosomal degradation processes, vesicular traffic, and lysosomal biogenesis to evoke the diverse pathophysiology that is evident in this complex set of disorders.

1 February 2011 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
PDF file
HJHilary F. Jones
Hilary F. Jones
RBRoss N. Butler
Ross N. Butler
Doug BrooksDoug Brooks
Doug Brooks
Fructose is a hexose sugar that is being increasingly consumed in its monosaccharide form. Patients who exhibit fructose malabsorption can present with gastrointestinal symptoms that include chronic diarrhea and abdominal pain. However, with no clearly established gastrointestinal mechanism for fructose malabsorption, patient analysis by the proxy of a breath hydrogen test (BHT) is controversial. The major transporter for fructose in intestinal epithelial cells is thought to be the facilitative transporter GLUT5. Consistent with a facilitative transport system, we show here by analysis of past studies on healthy adults that there is a significant relationship between fructose malabsorption and fructose dose ( r = 0.86, P < 0.001). Thus there is a dose-dependent and limited absorption capacity even in healthy individuals. Changes in fructose malabsorption with age have been observed in human infants, and this may parallel the developmental regulation of GLUT5 expression. Moreover, a GLUT5 knockout mouse has displayed the hallmarks associated with profound fructose malabsorption. Fructose malabsorption appears to be partially modulated by the amount of glucose ingested. Although solvent drag and passive diffusion have been proposed to explain the effect of glucose on fructose malabsorption, this could possibly be a result of the facilitative transporter GLUT2. GLUT5 and GLUT2 mRNA have been shown to be rapidly upregulated by the presence of fructose and GLUT2 mRNA is also upregulated by glucose, but in humans the distribution and role of GLUT2 in the brush border membrane are yet to be definitively decided. Understanding the relative roles of these transporters in humans will be crucial for establishing a mechanistic basis for fructose malabsorption in gastrointestinal patients.

31 March 2021 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
MWMark Ward
Mark Ward
Laura KaneLaura Kane
Laura Kane
LNLucy Norris
Lucy Norris
BMBashir M. Mohamed
Bashir M. Mohamed
TKTanya Kelly
Tanya Kelly
JOJohn J. O’lEary
John J. O’lEary
Cancer cells that transit from primary tumours into the circulatory system are known as circulating tumour cells (CTCs). These cancer cells have unique phenotypic and genotypic characteristics which allow them to survive within the circulation, subsequently extravasate and metastasise. CTCs have emerged as a useful diagnostic tool using “liquid biopsies” to report on the metastatic potential of cancers. However, CTCs by their nature interact with components of the blood circulatory system on a constant basis, influencing both their physical and morphological characteristics as well as metastatic capabilities. These properties and the associated molecular profile may provide critical diagnostic and prognostic capabilities in the clinic. Platelets interact with CTCs within minutes of their dissemination and are crucial in the formation of the initial metastatic niche. Platelets and coagulation proteins also alter the fate of a CTC by influencing EMT, promoting pro-survival signalling and aiding in evading immune cell destruction. CTCs have the capacity to directly hijack immune cells and utilise them to aid in CTC metastatic seeding processes. The disruption of CTC clusters may also offer a strategy for the treatment of advance staged cancers. Therapeutic disruption of these heterotypical interactions as well as direct CTC targeting hold great promise, especially with the advent of new immunotherapies and personalised medicines. Understanding the molecular role that platelets, immune cells and the coagulation cascade play in CTC biology will allow us to identify and characterise the most clinically relevant CTCs from patients. This will subsequently advance the clinical utility of CTCs in cancer diagnosis/prognosis.

12 July 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
ETEunice E. To
Eunice E. To
RVRoss Vlahos
Ross Vlahos
RLRaymond Luong
Raymond Luong
MHMichelle L. Halls
Michelle L. Halls
PRPatrick Reading
Patrick Reading
SSSTAVROS SELEMIDIS
STAVROS SELEMIDIS
The imminent threat of viral epidemics and pandemics dictates a need for therapeutic approaches that target viral pathology irrespective of the infecting strain. Reactive oxygen species are ancient processes that protect plants, fungi and animals against invading pathogens including bacteria. However, in mammals reactive oxygen species production paradoxically promotes virus pathogenicity by mechanisms not yet defined. Here we identify that the primary enzymatic source of reactive oxygen species, NOX2 oxidase, is activated by single stranded RNA and DNA viruses in endocytic compartments resulting in endosomal hydrogen peroxide generation, which suppresses antiviral and humoral signaling networks via modification of a unique, highly conserved cysteine residue (Cys98) on Toll-like receptor-7. Accordingly, targeted inhibition of endosomal reactive oxygen species production abrogates influenza A virus pathogenicity. We conclude that endosomal reactive oxygen species promote fundamental molecular mechanisms of viral pathogenicity, and the specific targeting of this pathogenic process with endosomal-targeted reactive oxygen species inhibitors has implications for the treatment of viral disease.

23 December 2021 in Cells
Verified
Journal Article
Open access
PDF file
Shane HickeyShane Hickey
Shane Hickey
BUBenjamin Ung
Benjamin Ung
CBChristie Bader
Christie Bader
Robert Douglas BrooksRobert Douglas Brooks
Robert Douglas Brooks
JLJoanna Lazniewska
Joanna Lazniewska
Doug BrooksDoug Brooks
Doug Brooks
Fluorescence microscopy has become a critical tool for researchers to understand biological processes at the cellular level. Micrographs from fixed and live-cell imaging procedures feature in a plethora of scientific articles for the field of cell biology, but the complexities of fluorescence microscopy as an imaging tool can sometimes be overlooked or misunderstood. This review seeks to cover the three fundamental considerations when designing fluorescence microscopy experiments: (1) hardware availability; (2) amenability of biological models to fluorescence microscopy; and (3) suitability of imaging agents for intended applications. This review will help equip the reader to make judicious decisions when designing fluorescence microscopy experiments that deliver high-resolution and informative images for cell biology.